Roche’s Genentech unit reported new head-to-head Phase 3 data showing its KRAS G12C inhibitor divarasib outperformed approved therapies in previously treated non-small-cell lung cancer. In the Krascendo-1 trial, Roche said divarasib delivered statistically significant improvements in both overall survival and progression-free survival versus Amgen’s Lumakras and Bristol Myers Squibb’s Krazati, with no new safety signals. Genentech said it expects to submit the data to regulators and present details at an upcoming medical meeting, aiming to strengthen its effort to establish divarasib as a standard-of-care option in second-line KRAS G12C NSCLC. The update intensifies competition in a market still shaped by first-generation KRAS G12C inhibitors and growing sequencing and resistance strategies for targeted lung cancer care.